Xeris Biopharma (NASDAQ:XERS) Insider Sells $176,341.56 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider John Patrick Shannon, Jr. sold 24,907 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $7.08, for a total value of $176,341.56. Following the sale, the insider directly owned 2,705,346 shares of the company’s stock, valued at $19,153,849.68. The trade was a 0.91% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Xeris Biopharma Stock Up 12.8%

NASDAQ:XERS opened at $8.13 on Friday. The company’s 50 day moving average is $7.40 and its 200-day moving average is $7.14. Xeris Biopharma Holdings, Inc. has a 12 month low of $3.14 and a 12 month high of $10.08. The firm has a market cap of $1.35 billion, a price-to-earnings ratio of -81.29 and a beta of 0.50.

Xeris Biopharma (NASDAQ:XERS) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.00 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.01). The company had revenue of $74.38 million for the quarter, compared to analyst estimates of $74.19 million. Research analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current fiscal year.

Institutional Trading of Xeris Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of the company. Cetera Investment Advisers raised its stake in shares of Xeris Biopharma by 3.9% in the second quarter. Cetera Investment Advisers now owns 46,332 shares of the company’s stock valued at $216,000 after purchasing an additional 1,735 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Xeris Biopharma by 7.6% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 32,167 shares of the company’s stock valued at $150,000 after buying an additional 2,264 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of Xeris Biopharma by 7.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 54,472 shares of the company’s stock valued at $254,000 after buying an additional 3,562 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Xeris Biopharma by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock valued at $461,000 after buying an additional 3,594 shares in the last quarter. Finally, Federated Hermes Inc. lifted its holdings in shares of Xeris Biopharma by 0.5% during the 2nd quarter. Federated Hermes Inc. now owns 691,381 shares of the company’s stock worth $3,229,000 after acquiring an additional 3,598 shares during the period. 42.75% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

XERS has been the topic of a number of recent analyst reports. Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Saturday, November 8th. Piper Sandler lifted their price target on Xeris Biopharma from $6.00 to $8.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Zacks Research lowered Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 30th. Barclays began coverage on shares of Xeris Biopharma in a research note on Monday, December 8th. They issued an “overweight” rating and a $9.00 price objective on the stock. Finally, Oppenheimer reaffirmed an “outperform” rating and set a $18.00 target price on shares of Xeris Biopharma in a research report on Friday, November 7th. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $9.50.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.